Immunology
From the Journals
Vaccination status doesn’t impact infectivity timeline in kids
”Current policies requiring isolation for 5 days after a positive test might be appropriate, as the majority of children were not infectious by...
News from the FDA/CDC
New meningococcal vaccine wins FDA approval
The vaccine “has the potential to protect more adolescents and young adults from this severe and unpredictable disease by providing the broadest...
Conference Coverage
Asthma with EoE linked to earlier hospitalization
Double atopic disease could be causing more inflammation, but more research is needed.
Conference Coverage
Asthma severity higher among LGBTQ+ population
SGM respondents were significantly more likely to have had asthma attacks requiring steroid use in the past years.
Conference Coverage
New RSV vaccine will cut hospitalizations, study shows
With widespread use of the vaccine, annual hospitalizations resulting from infant RSV would fall by 51%, emergency department encounters would...
Commentary
Atopic dermatitis: Five things to know
The incidence of AD has increased over the past several decades, and environmental factors such as climate change have been implicated as a...
Latest News
Patch testing finds higher prevalence of ACD among children with AD
AD and ACD both present with red, itchy, eczema-like patches and plaques and can be “really hard to differentiate.”
Case Reports
52-year-old man • intermittent fevers • recently received second dose of COVID-19 vaccine • tremors in all 4 extremities • Dx?
► Intermittent fevers
► Recently received second dose of COVID-19 vaccine
► Tremors in all 4 extremities
From the Journals
Maternal pertussis vax effective for infants in most vulnerable months
Large study also helps answer questions on duration of effectiveness and the potential “blunting” effect in infants.
News from the FDA/CDC
FDA approves first tocilizumab biosimilar
Tocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated.
Latest News
FDA issues letter regarding lebrikizumab review for atopic dermatitis
The agency cited concerns related to an inspection of a third-party contract manufacturer.